Literature DB >> 2652319

Navelbine: a new step in cancer therapy?

J P Armand1, M Marty.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2652319

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  7 in total

Review 1.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

2.  Overview of new treatments for breast cancer.

Authors:  G N Hortobagyi
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  Vinorelbine: an active, non cross-resistant drug in advanced breast cancer. Results from a phase II study.

Authors:  M Terenziani; R Demicheli; C Brambilla; L Ferrari; A Moliterni; M Zambetti; A Caraceni; C Martini; G Bonadonna
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Authors:  Laurent Nguyen; Brigitte Tranchand; Christian Puozzo; Philippe Variol
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

5.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Pharmacokinetics of navelbine after oral administration in cancer patients.

Authors:  X J Zhou; P Boré; S Monjanel; Z Sahnoun; R Favre; A Durand; R Rahmani
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 7.  Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.

Authors:  S O'Reilly; M J Kennedy; E K Rowinsky; R C Donehower
Journal:  Breast Cancer Res Treat       Date:  1995       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.